Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones.

Apr. 19, 2026 at 10:38pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a sleek, metallic medical device or pharmaceutical vial placed elegantly on a clean, monochromatic background, conceptually representing innovation and advancement in the cancer treatment industry.A potential $2 billion acquisition of a biotech firm focused on cutting-edge cancer therapies could bolster Eli Lilly's presence in the lucrative and competitive oncology market.Boston Today

U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, according to a report from The Wall Street Journal. The potential deal would strengthen Lilly's cancer portfolio and bolster its presence in the fast-growing but competitive cancer treatment market.

Why it matters

The acquisition of Kelonia Therapeutics would expand Eli Lilly's capabilities in the lucrative and rapidly evolving cancer therapeutics space, particularly in the area of CAR-T cell therapies, which are a promising new approach to treating certain types of cancer.

The details

Kelonia Therapeutics is a clinical-stage biotech company developing a pipeline of genetic medicines, with a focus on CAR-T cell therapies that modify a patient's immune cells to recognize and destroy cancer cells. A deal between Eli Lilly and Kelonia could include additional payments tied to Kelonia meeting certain milestones. The potential acquisition would strengthen Lilly's cancer portfolio, which includes therapies like Jaypirca and Verzenio, as the company looks to bolster its presence in the competitive cancer treatment market.

  • The Wall Street Journal reported on the potential deal on Sunday, April 19, 2026.
  • A deal could be reached as soon as Monday, April 20, 2026.

The players

Eli Lilly

A U.S. drugmaker that is in advanced talks to acquire Kelonia Therapeutics.

Kelonia Therapeutics

A clinical-stage biotech company developing a pipeline of genetic medicines, with a focus on CAR-T cell therapies.

Got photos? Submit your photos here. ›

What’s next

If a deal is reached, Eli Lilly will likely provide more details on the acquisition and its plans for integrating Kelonia Therapeutics and its pipeline of cancer therapies.

The takeaway

The potential acquisition of Kelonia Therapeutics by Eli Lilly highlights the pharmaceutical industry's ongoing focus on expanding cancer treatment capabilities, particularly in emerging areas like CAR-T cell therapies, as companies seek to stay competitive in the fast-growing and lucrative oncology market.